未登录
分享
收藏
分享
收藏RM-046, a first-in-class, mutant-selective, and oral KRASQ61H(ON) inhibitor that drives tumor regression in preclinical models and validates KRASQ61H as a therapeutic target
Yang, Yu C.; Thompson, Severin; Montgomery, David; Quinones, Antonio J.; Wei, Xing; Madej, Benjamin; Tomlinson, Aidan; Shifrin, Nataliya T.; McNamara, Alexander; Ahler, Ethan; McDowell, Laura L.; Flagella, Michael; Setser, John; Chang, Stephanie; Wang, Zhican; Wang, Zhengping; Huang, Jun; Ballmer, Steve; Li, Shaong; Buckl, Andreas; Koltun, Elena; Gill, Adrian; Jiang, Jingjing; Singh, Mallika; Smith, Jacqueline A.
分享
收藏
分享
收藏
分享
收藏
分享
收藏
分享
收藏